New test aims to predict cancer treatment success before it starts
NCT ID NCT06536257
Summary
This study is testing a new predictive tool to see if it can accurately forecast which patients with melanoma and other cancers will respond to immunotherapy treatments. It will enroll 1,000 patients who are eligible for standard immunotherapy. The goal is to see if this tool can help doctors make more personalized treatment decisions by identifying patients unlikely to benefit from standard options early on.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
RECRUITINGSydney, New South Wales, 2050, Australia
Contact
Contact Email: •••••@•••••
-
Melanoma Institute Australia
RECRUITINGSydney, New South Wales, 2065, Australia
Contact
Contact
Contact Email: •••••@•••••
Contact
Contact
Contact
Contact
-
Westmead Hospital
RECRUITINGSydney, New South Wales, 2145, Australia
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.